Smooth Drug Development August 2025 News Release

Monthly News – August 2025

At Smooth Drug Development, we are excited to share the latest updates and achievements from August 2025:

New Projects

We are delighted to announce several new collaborations and ongoing initiatives:

• A phase II clinical trial for a US Biotech is launching in Pakistan and Uzbekistan, further strengthening our regional presence in Central and South Asia.
• The ADC project is progressing successfully, and we are proud to share that we have been officially selected for this collaboration.
• We signed a full-service contract for a Phase III clinical trial involving Sertaconazole.
• We signed a Phase III clinical trial involving Alginic Acid.
• A Pharma company has entrusted us with two new projects in gynecology, further strengthening our partnership.

Clinical and Scientific Departments News:

Our clinical teams continue to deliver outstanding progress:

• Phase III Hematology Trial: The CSR has been successfully accepted by the Sponsor. Our team was invited to participate in PI meeting on the study results. We were also selected to prepare an article on the study results of this novel drug.
• Phase III Hepatitis Delta Trial: SDD is in process of contract execution with the global Sponsor to deliver an international clinical trial of novel hepatitis Delta treatment in Pakistan and Uzbekistan. Clinical trial applications for regulatory approval are scheduled for early September 2025 in both countries.
• Phase I Orphan Disease Trial: Site Initiation Visit was successfully performed on 26th August.
• Pembrolizumab Study: The last patient completed the study.
• Women’s Health Phase III Trial: 19 Site Selection Visits were conducted.

Business Development News:

Key Partner Engagements:

• We officially launched our LinkedIn newsletter page “Smooth Drug Development News” in mid-August and are proud to have reached 477 subscribers within just two weeks.
• Our BD team is preparing to attend CPHI Frankfurt 2025 (28–30 October), where we look forward to engaging with industry leaders and exploring new collaborations.